COST-EFFECTIVENESS ANALYSIS OF PLUS ASPIRIN VS PLACEBO PLUS ASPIRIN IN THE TREATMENT OF ISCHEMIC STROKE BASED ON A RANDOMIZED CLINICAL TRIAL

被引：0
|
作者：
Xiang, Y. [1 ]
Fan, W. [2 ]
Zhou, L. [3 ]
Guo, Z. [3 ]
Zhou, N. [3 ]
Yang, N. [3 ]
Hu, M. [3 ]
机构：
[1] Sichuan Univ, Chengdu 51, Peoples R China
[2] West China Second Univ Hosp, Chengdu, Peoples R China
[3] Sichuan Univ, Chengdu, Peoples R China
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV21
引用
收藏
页码：S93 / S93
页数：1
相关论文
共 50 条
  • [31] Edoxaban versus placebo, aspirin, or aspirin plus clopidogrel for stroke prevention in atrial fibrillation An indirect comparison analysis
    Blann, Andrew D.
    Skjoth, Flemming
    Rasmussen, Lars H.
    Larsen, Torben B.
    Lip, Gregory Y. H.
    THROMBOSIS AND HAEMOSTASIS, 2015, 114 (02) : 403 - 409
  • [32] Aspirin plus dipyridamole combination therapy effective for ischemic stroke
    Josephson, S. Andrew
    POSTGRADUATE MEDICINE, 2006, 119 (02) : 55 - 55
  • [33] Celecoxib plus aspirin versus naproxen and lansoprazole plus aspirin: A randomized, double-blind, endoscopic trial
    Goldstein, Jay L.
    Cryer, Byron
    Amer, Fouad
    Hunt, Barbara
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2007, 5 (10) : 1167 - 1174
  • [34] High-risk acute coronary syndromes: cost-effectiveness of clopidogrel plus aspirin
    Nature Clinical Practice Cardiovascular Medicine, 2005, 2 (5): : 229 - 230
  • [35] Ticagrelor plus aspirin vs clopidogrel plus aspirin in mild non-cardioembolic ischemic stroke: A protocol of a randomized, controlled, active comparator arm, outcome assessor blind, feasibility study
    Sharifi-Razavi, Athena
    Ahmadi, Amir Moghadam
    Tabrizi, Nasim
    Daz, Razieh
    NEUROLOGY ASIA, 2023, 28 (03) : 535 - 540
  • [36] COST-EFFECTIVENESS ANALYSIS OF TENECTEPLASE VS ALTEPLASE FOR TREATMENT OF ACUTE ISCHEMIC STROKE
    Dasari, D.
    Deshmukh, A. A.
    VALUE IN HEALTH, 2020, 23 : S268 - S268
  • [37] Aspirin as a Treatment for ARDS A Randomized, Placebo-Controlled Clinical Trial
    Toner, Philip
    Boyle, Andrew J.
    McNamee, James J.
    Callaghan, Kathryn
    Nutt, Christopher
    Johnston, Paul
    Trinder, John
    McFarland, Margaret
    Verghis, Rejina
    McAuley, Daniel F.
    O'Kane, Cecilia M.
    CHEST, 2022, 161 (05) : 1275 - 1284
  • [38] The cost-effectiveness of rivaroxaban with or without aspirin in the COMPASS trial
    Lamy, Andre
    Eikelboom, John
    Tong, Wesley
    Yuan, Fei
    Bangdiwala, Shrikant, I
    Bosch, Jackie
    Connolly, Stuart
    Lonn, Eva
    Dagenais, Gilles R.
    Branch, Kelley R. H.
    Wang, Wei-Jhih
    Bhatt, Deepak L.
    Probstfield, Jeff
    Ertl, Georg
    Stoerk, Stefan
    Steg, P. Gabriel
    Aboyans, Victor
    Durand-Zaleski, Isabelle
    Ryden, Lars
    Yusuf, Salim
    EUROPEAN HEART JOURNAL-QUALITY OF CARE AND CLINICAL OUTCOMES, 2023, 9 (05) : 502 - 510
  • [39] A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: Clopidogrel plus aspirin versus aspirin alone
    Schleinitz, MD
    Heidenreich, PA
    ANNALS OF INTERNAL MEDICINE, 2005, 142 (04) : 251 - 259
  • [40] Economic Evaluation of Ticagrelor Plus Aspirin Versus Aspirin Alone for Acute Ischemic Stroke and Transient Ischemic Attack
    Chen, Jigang
    Ji, Linjin
    Tong, Xin
    Han, Mingyang
    Zhao, Songfeng
    Qin, Yongkai
    He, Zilong
    Jiang, Zhiqun
    Liu, Aihua
    FRONTIERS IN PHARMACOLOGY, 2022, 13
12345